{"id":650041,"date":"2023-05-02T17:08:01","date_gmt":"2023-05-02T17:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=650041"},"modified":"2023-05-02T17:08:01","modified_gmt":"2023-05-02T17:08:01","slug":"generalized-pustular-psoriasis-gpp-market-analysis-market-size-epidemiology-leading-companies-companies-novartis-kyowa-hakko-kirin-abbvie-boehringer-ingelheim-eisai","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/generalized-pustular-psoriasis-gpp-market-analysis-market-size-epidemiology-leading-companies-companies-novartis-kyowa-hakko-kirin-abbvie-boehringer-ingelheim-eisai_650041.html","title":{"rendered":"Generalized Pustular Psoriasis (GPP) Market Analysis, Market Size, Epidemiology, Leading Companies | Companies – Novartis, Kyowa Hakko Kirin, AbbVie, Boehringer Ingelheim, Eisai"},"content":{"rendered":"
\n
\"Generalized<\/a><\/div>\n
\n
Generalized Pustular Psoriasis Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cGeneralized Pustular Psoriasis (GPP)\u2013Market Insights, Epidemiology, and Market Forecast-2032\u201d report delivers an in-depth understanding of the Generalized Pustular Psoriasis (GPP), historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis (GPP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Generalized Pustular Psoriasis (GPP)-Market Insights, Epidemiology, and Market Forecast-2032”.<\/strong><\/p>\n

DelveInsight’s “Generalized Pustular Psoriasis (GPP)–Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>” report delivers an in-depth understanding of the Generalized Pustular Psoriasis (GPP), historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis (GPP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the  Generalized Pustular Psoriasis Market Report 2032<\/a>:<\/strong><\/p>\n

 <\/p>\n

    \n
  1. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males.  <\/li>\n
  2. According to DelveInsight, the total diagnosed prevalent Population of GPP in the 7MM was assessed to be more than 14,000 in 2019.  <\/li>\n
  3. Our estimates suggest the highest diagnosed prevalence of GPP in the United States with close to 6,000 cases in 2019. Furthermore, among the EU-5 countries, France had the highest diagnosed prevalent population of GPP, followed by Germany and the United Kingdom. <\/li>\n
  4. On the other hand, Spain was assessed with the lowest diagnosed prevalent population  DelveInsight’s estimations showed that Japan had around 2,000 prevalent cases for GPP in 2019<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Generalized Pustular Psoriasis (GPP) market report covers a descriptive overview and comprehensive insight of the Generalized Pustular Psoriasis (GPP) epidemiology and Generalized Pustular Psoriasis (GPP) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Generalized Pustular Psoriasis (GPP) market report provides insights into the current and emerging therapies.<\/p>\n

    3.Generalized Pustular Psoriasis (GPP) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Generalized Pustular Psoriasis (GPP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Generalized Pustular Psoriasis (GPP) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/generalized-pustular-psoriasis-market<\/a><\/strong><\/p>\n

    Generalized Pustular Psoriasis (GPP): Overview<\/strong><\/p>\n

    Generalized pustular psoriasis (GPP) is an extremely rare type of psoriasis that can present in a variety of forms. Unlike the most general and common forms of psoriasis, GPP usually covers the entire body and with pus-filled blisters rather than plaques. GPP can present at any age, but is rarer in young children.<\/p>\n

    The key players involved in the Generalized Pustular Psoriasis (GPP) market<\/a>:<\/strong><\/p>\n

     <\/p>\n

      \n
    1. Janssen Pharmaceuticals<\/li>\n
    2. Novartis<\/li>\n
    3. Kyowa Hakko Kirin<\/li>\n
    4. AbbVie\/Boehringer Ingelheim<\/li>\n
    5. AbbVie\/Eisai<\/li>\n
    6. Eli Lilly & Company<\/li>\n
    7. Mitsubishi Tanabe Pharma<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Generalized Pustular Psoriasis (GPP) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. Tremfya<\/li>\n
      2. COSENTYX<\/li>\n
      3. Lumicef<\/li>\n
      4. Humira<\/li>\n
      5. Taltz<\/li>\n
      6. Remicade<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/generalized-pustular-psoriasis-market<\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Generalized Pustular Psoriasis (GPP) Patient Share (%) Overview at a Glance<\/p>\n

        5. Generalized Pustular Psoriasis (GPP) Market Overview at a Glance<\/p>\n

        6. Generalized Pustular Psoriasis (GPP) Disease Background and Overview<\/p>\n

        7. Generalized Pustular Psoriasis (GPP) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Generalized Pustular Psoriasis (GPP) <\/p>\n

        9. Generalized Pustular Psoriasis (GPP) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Generalized Pustular Psoriasis (GPP) Emerging Therapies<\/p>\n

        12. Generalized Pustular Psoriasis (GPP) Market Outlook<\/p>\n

        13. Country-Wise Generalized Pustular Psoriasis (GPP) Market Analysis (2019–2032)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Generalized Pustular Psoriasis (GPP) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        Generalized Pustular Psoriasis Market DelveInsight\u2019s \u201cGeneralized Pustular Psoriasis (GPP)\u2013Market Insights, Epidemiology, and Market Forecast-2032\u201d report delivers an in-depth understanding of the Generalized Pustular Psoriasis (GPP), historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis (GPP) market trends in … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-650041","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=650041"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650041\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=650041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=650041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=650041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}